EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Engineered Fab glycosylation of a blood-brain barrier transporter single-chain variable fragment preserved functionality but did not impact anti-drug antibody formation

Gustaf Hederoth, Jimmy Ytterberg, Jielu Liu, Ana Godec, Abhitha Kodundirapally Venkataramakrishnan, Nicole G. Metzendorf, Bence Rethi, Greta Hultqvist

PLOS One · 20.11.2026 · 21 (11) · e0355570

DOI: 10.1371/journal.pone.0355570 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS One, online erschienen am 20.11.2026. Verfasst von Gustaf Hederoth und 7 weiteren Autor:innen. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Vetenskapsrådet, Åhlén-stiftelsen, Magnus Bergvalls Stiftelse.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Sialylation of N-linked glycans can critically influence protein immunogenicity, potentially conferring immunosuppressive properties and an extended half-life. Anti-drug antibodies (ADAs) formed against protein therapeutics can substantially limit drug efficacy. In this study, we investigated whether introducing sialic acid residues into a therapeutic construct would reduce ADA responses, using the single-chain variable fragment (scFv) of the 8D3 antibody as a model protein. When fused to therapeutic antibodies, scFv8D3 enables blood-brain barrier transport via transferrin receptor-mediated transcytosis, however, it also increases immunogenicity of the construct and the consequent ADA production. We generated two novel scFv8D3 variants with distinct N-linked glycosylation motifs (NXT/S), which both displayed sialic acid residues and retained functionality, as evidenced by the preservation of transferrin receptor binding and brain uptake. However, Fab glycosylation did not significantly alter pharmacokinetics or ADA production in mice. Our findings demonstrated that introducing Fab glycosylation is feasible, without compromising biological activity. Nonetheless, this strategy alone was insufficient to mitigate immunogenicity, underscoring the need for alternative approaches to improve the long-term safety of protein therapeutics.

Förderung

  • Vetenskapsrådet
  • Åhlén-stiftelsen
  • Magnus Bergvalls Stiftelse
  • VINNOVA
  • Alzheimerfonden
  • Olle Engkvists Stiftelse
  • Parkinsonfonden
  • Bissen Brainwalk

Zitieren

APA

Hederoth, G., Ytterberg, J., Liu, J., Godec, A., Venkataramakrishnan, A. K., Metzendorf, N. G., Rethi, B., & Hultqvist, G. (2026). Engineered Fab glycosylation of a blood-brain barrier transporter single-chain variable fragment preserved functionality but did not impact anti-drug antibody formation. PLOS One, 21(11), e0355570. https://doi.org/10.1371/journal.pone.0355570

Vancouver

Hederoth G, Ytterberg J, Liu J, Godec A, Venkataramakrishnan AK, Metzendorf NG, et al. Engineered Fab glycosylation of a blood-brain barrier transporter single-chain variable fragment preserved functionality but did not impact anti-drug antibody formation. PLOS One. 2026;21(11):e0355570. doi:10.1371/journal.pone.0355570

BibTeX
@article{Hederoth2026,
  author = {Hederoth, Gustaf and Ytterberg, Jimmy and Liu, Jielu and Godec, Ana and Venkataramakrishnan, Abhitha Kodundirapally and Metzendorf, Nicole G. and Rethi, Bence and Hultqvist, Greta},
  title = {Engineered Fab glycosylation of a blood-brain barrier transporter single-chain variable fragment preserved functionality but did not impact anti-drug antibody formation},
  journal = {PLOS One},
  year = {2026},
  volume = {21},
  number = {11},
  pages = {e0355570},
  doi = {10.1371/journal.pone.0355570}
}
Kostenlos starten →